Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by American Century Companies Inc.

American Century Companies Inc. grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 660,595 shares of the biopharmaceutical company’s stock after purchasing an additional 23,943 shares during the quarter. American Century Companies Inc. owned 0.63% of Regeneron Pharmaceuticals worth $371,436,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Salomon & Ludwin LLC bought a new position in Regeneron Pharmaceuticals during the third quarter valued at about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $31,000. Caitlin John LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $34,000. Traub Capital Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $38,000. Finally, E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 87.5% in the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 35 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.4%

REGN stock opened at $781.67 on Friday. The company has a 50 day moving average of $771.59 and a two-hundred day moving average of $680.78. The company has a market cap of $82.64 billion, a price-to-earnings ratio of 18.81, a PEG ratio of 2.07 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The business had revenue of $3.88 billion for the quarter, compared to the consensus estimate of $3.76 billion. During the same period in the prior year, the business posted $12.07 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% compared to the same quarter last year. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be given a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, February 20th. This is an increase from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s payout ratio is currently 9.05%.

Insider Transactions at Regeneron Pharmaceuticals

In other news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares in the company, valued at $1,362,400. The trade was a 46.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Huda Y. Zoghbi sold 1,638 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,330,604.99. This represents a 49.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 5,274 shares of company stock valued at $4,142,738 over the last 90 days. Company insiders own 7.02% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA expanded Dupixent’s U.S. label to include allergic fungal rhinosinusitis in patients aged 6 and up, broadening the drug’s addressable market and adding near‑term upside to revenue forecasts. Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds
• Positive Sentiment: The European Medicines Agency (CHMP) recommended Dupixent for approval to treat chronic spontaneous urticaria (CSU) in children aged 2–11 — if approved this would be the first targeted EU therapy for that pediatric indication, supporting incremental EU sales alongside Sanofi. Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children
• Positive Sentiment: Dupixent remains the growth engine — recent coverage highlights strong sales growth (Dupixent +22.8% y/y in Q4) and continued investor confidence that the franchise can drive Regeneron’s top‑line and multiple expansion. Why Dupixent Keeps Regeneron A Top Big Pharma Pick
• Positive Sentiment: Hedge funds and institutional investors are highlighting Regeneron as a top gene‑therapy/biotech holding, boosting sentiment around the stock’s longer‑term growth story. Why Regeneron Pharmaceuticals (REGN) is One of the Top Gene Therapy Stocks to Buy According to Hedge Funds
• Neutral Sentiment: A sector peer (Intellia) reported strong Q4 results and its shares jumped, reflecting ongoing investor appetite for gene‑editing / biotech winners; this may lift sector flows but is not specific to Regeneron’s fundamentals. Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
• Negative Sentiment: Some coverage notes Regeneron has underperformed the Nasdaq over the past year, which could cap short‑term multiple expansion despite product wins — a cautionary note for momentum traders. Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Analyst Upgrades and Downgrades

Several analysts recently commented on REGN shares. UBS Group increased their target price on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday, December 29th. Guggenheim increased their price objective on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Cantor Fitzgerald lifted their target price on Regeneron Pharmaceuticals from $740.00 to $800.00 and gave the stock an “overweight” rating in a report on Monday, February 2nd. Finally, Wells Fargo & Company boosted their target price on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $793.81.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.